CDK-IN-18

• Description:

  CDK-IN-18 (Compound EX.161) is an orally active, brain-penetrant and selective inhibitor of CDK2, CDK4, and CDK6. CDK-IN-18 inhibits the activity of cyclin-CDK complexes, blocks phosphorylation of the retinoblastoma protein (pRb), arresting the cell cycle transition from G1 to S phase. CDK-IN-18 is promising for research of cancers, such as breast cancer (especially hormone receptor-positive, HER2-negative type), lung cancer, and colorectal cancer[1][2].

• UNSPSC:

  12352005

• Target:

  CDK

• Related Pathways:

  Cell Cycle/DNA Damage

• Field of Research:

  Cancer

• Smiles:

  CC(C1=C2N(N=C1)C=CC(C3=NC(NC4=CC=C(N5C(C[C@H](CC5)N(C)C)=O)C=N4)=NC=C3)=C2)C

• Molecular Formula:

  C26H30N8O

• Molecular Weight:

  470.57

• References & Citations:

  [1]Zhilong Hu, et al. Cdk inhibitors. WO2020224568A1. 2020-11-12.|[2]Xiaotian Zhu, et al. Salt and solid forms of a cdk inhibitor. WO2025103447A1. 2025-05-22.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDK2; CDK4; CDK6

• CAS Number:

  [2531743-46-9]